Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 24 10:13AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.78 Insider Own42.05% Shs Outstand6.05M Perf Week-10.28%
Market Cap4.64M Forward P/E- EPS next Y-0.28 Insider Trans2.07% Shs Float4.41M Perf Month-5.57%
Income-4.74M PEG- EPS next Q-0.13 Inst Own4.99% Short Float0.50% Perf Quarter-20.78%
Sales0.48M P/S9.67 EPS this Y50.65% Inst Trans- Short Ratio0.85 Perf Half Y-39.00%
Book/sh0.36 P/B1.68 EPS next Y26.32% ROA-122.37% Short Interest0.02M Perf Year-72.15%
Cash/sh0.28 P/C2.20 EPS next 5Y- ROE-148.74% 52W Range0.57 - 2.71 Perf YTD-40.20%
Dividend Est.- P/FCF- EPS past 5Y-189.86% ROI-183.46% 52W High-77.49% Beta0.68
Dividend TTM- Quick Ratio5.46 Sales past 5Y20.14% Gross Margin- 52W Low7.02% ATR (14)0.04
Dividend Ex-Date- Current Ratio5.46 EPS Y/Y TTM-52.07% Oper. Margin-1021.92% RSI (14)39.87 Volatility6.73% 5.33%
Employees7 Debt/Eq0.05 Sales Y/Y TTM77.45% Profit Margin-993.39% Recom1.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q12.10% Payout- Rel Volume0.07 Prev Close0.57
Sales Surprise0.00% EPS Surprise0.00% Sales Q/Q23.58% EarningsMay 29 Avg Volume26.12K Price0.61
SMA20-5.50% SMA50-12.43% SMA200-40.59% Trades Volume288 Change7.02%
May-31-24 08:00AM
May-29-24 12:53PM
May-24-24 01:53PM
May-21-24 08:00AM
08:00AM Loading…
Apr-17-24 08:00AM
Apr-05-24 08:00AM
Apr-03-24 08:00AM
Mar-07-24 03:23PM
Mar-05-24 08:00AM
Feb-20-24 08:00AM
Dec-20-23 08:00AM
Nov-12-23 08:20PM
Nov-10-23 08:00AM
Oct-25-23 04:05PM
08:00AM Loading…
Oct-24-23 08:00AM
Oct-23-23 08:45AM
Oct-20-23 08:00AM
Sep-21-23 08:30AM
Jun-13-23 08:30AM
May-15-23 09:15AM
May-14-23 08:12AM
May-01-23 08:30AM
Apr-17-23 08:30AM
Apr-05-23 08:30AM
Mar-31-23 08:00AM
Mar-16-23 08:30AM
Mar-01-23 08:00AM
Jan-11-23 07:30AM
08:00AM Loading…
Jan-09-23 08:00AM
Dec-22-22 04:05PM
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaufman Jonathan HSee remarks below.May 14 '24Buy0.7610,0007,590898,849May 15 04:39 PM
Kaufman Jonathan HSee remarks below.Mar 19 '24Buy0.8725,00021,802888,849Mar 19 06:21 PM
Kaufman Jonathan HSee remarks below.Mar 18 '24Buy0.7930,00023,649863,849Mar 19 06:21 PM